Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 7/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | CCR1 | P32246 | 1/20 | 0.45 |
| ▸ | LSS | P48449 | 2/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 6/20 | 0.44 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.44 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.44 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3868658 | 0.88 | CHRM4 (0.66) | CHRM4CHRM1CHRM2CHRM5CHRM3 | |
| SCHEMBL6705872 | 0.87 | CHRM4 (0.67) | CHRM4CHRM1CHRM2CHRM5CHRM3 | |
| SCHEMBL6705916 | 0.87 | CHRM4 (0.69) | CHRM4CHRM1CHRM2CHRM5CHRM3 | |
| SCHEMBL6226177 | 0.86 | LSS (0.46) | CHRM4CHRM1HRH3CCR1LSS | |
| SCHEMBL6705886 | 0.85 | CHRM4 (0.55) | CHRM4CHRM1CHRM2CHRM5CHRM3 | |
| SCHEMBL6706014 | 0.79 | CHRM4 (0.54) | CHRM4CHRM1CHRM2CHRM5CHRM3 | |
| SCHEMBL6705906 | 0.79 | MCHR1 (0.52) | CHRM4CHRM1HRH3MCHR1TPSAB1 | |
| SCHEMBL6704534 | 0.78 | L3MBTL3 (0.59) | CHRM4CHRM1MCHR1TPSAB1TPSD1 | |
| SCHEMBL6704726 | 0.78 | MAPT (0.56) | CHRM4CHRM1HRH3MCHR1CYP2D6 | |
| SCHEMBL6705899 | 0.77 | CHRM4 (0.72) | CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040242572-A1 | New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242572-A1 | New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture | MCHR2, MCHR1, NPY1R | CHRM4 467/4885CHRM1 295/4885CHRM2 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.